Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.

@article{Schrump2006PhaseIS,
  title={Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.},
  author={D. S. Schrump and Maria R. Fischette and Dao M. Nguyen and Mingxing Zhao and Xinmin Li and Tricia F. Kunst and Ana R Hancox and Julie A. Hong and Guanyang Chen and Vitaliy Pishchik and William D. Figg and Anthony J. Murgo and Seth Steinberg},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2006},
  volume={12 19},
  pages={
          5777-85
        }
}
PURPOSE The DNA methylation paradox, manifested as derepression of cancer-testis antigens, and silencing of tumor suppressors during malignant transformation, provides the rationale for the utilization of chromatin remodeling agents for cancer therapy. A phase I trial was done to examine pharmacokinetics, toxicities, and gene expression mediated by 5-aza-2'-deoxycytidine (DAC) in patients with thoracic malignancies. EXPERIMENTAL DESIGN Thirty-five patients with cancers refractory to standard… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 83 CITATIONS

FILTER CITATIONS BY YEAR

2007
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 4 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES

Eval - uation of a 7 - day continuous intravenous infusion of decitabine : inhibition of promoter - specific and global genomic DNA methylation

  • SamlowskiWE, SA Leachman, M Wade
  • J Clin Oncol
  • 2005

Similar Papers

Loading similar papers…